HC Wainwright Issues Optimistic Estimate for ETON Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Stock analysts at HC Wainwright increased their FY2027 earnings estimates for Eton Pharmaceuticals in a research note issued to investors on Monday, January 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of $1.27 per share for the year, up from their prior forecast of $1.25. HC Wainwright currently has a “Buy” rating and a $17.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ FY2028 earnings at $1.62 EPS and FY2029 earnings at $2.31 EPS.

Separately, Craig Hallum lifted their target price on Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, October 28th.

Eton Pharmaceuticals Trading Down 1.4 %

Shares of ETON stock opened at $11.99 on Wednesday. The firm’s fifty day moving average price is $11.51 and its two-hundred day moving average price is $7.28. Eton Pharmaceuticals has a 1 year low of $3.03 and a 1 year high of $15.00. The firm has a market capitalization of $312.35 million, a P/E ratio of -54.50 and a beta of 1.38.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in Eton Pharmaceuticals during the third quarter worth $54,000. Jane Street Group LLC bought a new stake in shares of Eton Pharmaceuticals in the 3rd quarter valued at about $90,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Eton Pharmaceuticals by 86.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock valued at $390,000 after purchasing an additional 30,167 shares during the period. Renaissance Technologies LLC lifted its stake in Eton Pharmaceuticals by 63.8% in the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after purchasing an additional 41,469 shares during the last quarter. Finally, Stonepine Capital Management LLC bought a new position in Eton Pharmaceuticals during the second quarter worth about $362,000. 27.86% of the stock is owned by institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.